PRODUCTS

On July 23, 2012, the US Food and Drug Administration (FDA) approved Tudorza Pressair (active ingredient: adiponium bromide) for long-term maintenance of chronic obstructive pulmonary disease (COPD)-related bronchospasm (pulmonary gas) The road narrows, including chronic bronchitis and emphysema. COPD is a serious lung disease that causes difficulty in breathing. According to the National Heart, Lung, and Blood Institute, smoking is the leading cause of illness. In the United States, COPD is the fourth leading cause of death. Symptoms of patients with this disease include chest pain, chronic cough and phlegm. Tudorza Pressair is a long-acting anticholinergic dry powder inhaler that is applied twice daily to improve airflow by relieving muscles around the lungs.
Three randomized, placebo-controlled, confirmatory trials demonstrated the safety and efficacy of Tudorza Pressair, which included 1276 patients diagnosed with COPD over the age of 40 who had a history of smoking for at least one pack of cigarettes per day. year. Tudorza Pressair may cause serious adverse reactions, including abnormal bronchospasm, elevated or increased intraocular pressure (narrow-angle glaucoma), new or increased urinary retention. This medicine is not intended for the treatment of acute respiratory problems (acute bronchospasm) and is not recommended for patients <18 years of age. The most common adverse reactions reported included headache, nasopharyngitis and cough.